Virios therapeutics announces pricing of initial public offering

Atlanta--(business wire)--virios therapeutics, inc. (the “company”), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $30 million, before deducting underwriting discounts, commissions and offering expenses. in addition, the compan
VIRI Ratings Summary
VIRI Quant Ranking